OGI vs ACB

For growth investors, Aurora Cannabis Inc.

(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus 16. 4% for Organigram Global Inc. (OGI). Aurora Cannabis Inc. (ACB) offers the better valuation at 168. 8x trailing P/E, making it the more compelling value choice. Analysts rate Organigram Global Inc. (OGI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Organigram Global Inc.

(OGI) delivered a total return of -85. 8%, compared to -95. 8% for Aurora Cannabis Inc. (ACB). Over 10 years, the gap is even starker: ACB returned -92. 2% versus OGI's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Organigram Global Inc.

(OGI) is the lower-risk stock at 1. 33β versus Aurora Cannabis Inc. 's 1. 81β — meaning ACB is approximately 36% more volatile than OGI relative to the S&P 500. On balance sheet safety, Organigram Global Inc. (OGI) carries a lower debt/equity ratio of 3% versus 17% for Aurora Cannabis Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aurora Cannabis Inc.

(ACB) is pulling ahead at 27. 0% versus 16. 4% for Organigram Global Inc. (OGI). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to 70. 8% for Organigram Global Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurora Cannabis Inc.

(ACB) is the more profitable company, earning 0. 5% net margin versus -9. 6% for Organigram Global Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -34. 1% for OGI. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Organigram Global Inc.

(OGI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Aurora Cannabis Inc. (ACB) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OGI: -95. 6%, ACB: -92. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.